Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Eating Brie, Gouda, cheddar may lower dementia risk, new study says - 2What's the Fate of 5G Innovation?
- 3Consumers advised to dispose of 19 cooking pans due to lead leaching risk, FDA reports
- 4Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- 5Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- Longtime United Launch Alliance CEO Tory Bruno resigns from space company. 'Finished the mission I came to do.'
- Major railway disruptions persist as Germany braces for more snow
- Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know)
- The Most Astonishing Arising Advances to Watch
- Launch pad damaged as Russian rocket blasts off for space station, agency says
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- How to watch 'A Charlie Brown Christmas' for free in 2025
- Craig the beer-ambassador elephant dies aged 54
- Intriguing Strange Cruising Objections you Should Visit
